News
4h
Zacks Investment Research on MSNNovavax's COVID-Flu Combo Shot Shows Strong Immune ResponseNovavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...
Abcuro appointed former Priovant Therapeutics exec Courtney Cupples as chief commercial officer. Innospera Pharma appointed ...
U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it was \"plagued ...
Blueprint specializes in systemic mastocytosis, a rare immunological disease, and other Kit-driven diseases. With this ...
SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007 for Stargardt disease.
The National Agency for Food and Drug Administration and Control (NAFDAC) has banned an unregistered batch of the ...
Explore more
STOCKHOLM--Swedish buyout group EQT and French pharmaceutical major Sanofi co-led a $135 million series B financing round in Spanish biotech company SpliceBio. EQT co-led the funding round with Sanofi ...
Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support clinical development ...
Spain’s SpliceBio will use $135 million from a series B round backed by Sanofi and Roche to advance its lead gene editing ...
Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...
Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more
Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...
The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results